Literature DB >> 25006627

Gadoxetic acid disodium (Gd-EOBDTPA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis.

Lei Junqiang, Wang Yinzhong, Zhang Li, Guo Shunlin, Wang Xiaohui, Zhai Yanan, Yang Kehu.   

Abstract

PURPOSE: To evaluate the diagnostic value of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: A systematic, comprehensive literature search was conducted in PubMed (2004 [Gd-EOB-DTPA was first approved in Europe in 2004] to April 2013), Embase (2004 to April 2013), Web of Science (2004 to April 2013), and the Cochrane Library (2004 to April 2013). The Quality Assessment of Diagnostic Studies (QUADAS) items was used to evaluate the quality of the included studies. Stata 12.0 was used to analyze the data. Pooled sensitivity (SEN), pooled specificity (SPE), pooled positive likelihood ratio (PLR), pooled negative likelihood ratio (NLR), pooled diagnostic odds ratio (dOR), and summary receiver operating characteristic (SROC) curves were calculated to assess the diagnostic value of the individual diagnostic tests.
RESULTS: A total of 11 articles were included, involving 1578 nodules from four countries. The results of the meta-analysis showed that the pooled SEN, SPE, and SROC curve values were 0.92 (95% confidence interval [CI]: 0.89-0.94) 0.95 (95% CI: 0.93-0.97), and 0.98 (95% CI: 0.95-0.99), respectively, and subgroup analyses were performed.
CONCLUSION: Gd-EOB-DTPA-enhanced MRI has value for the detection of HCC; in particular, it has high sensitivity for the detection of lesions larger than 10 mm.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25006627     DOI: 10.1002/jmri.24354

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  10 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 2.  Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up.

Authors:  Stefano Colagrande; Francesco Regini; Gian Giacomo Taliani; Cosimo Nardi; Andrea Lorenzo Inghilesi
Journal:  World J Hepatol       Date:  2015-05-18

Review 3.  MR imaging probes: design and applications.

Authors:  Eszter Boros; Eric M Gale; Peter Caravan
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

Review 4.  Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Agostino Colli; Vanja Giljaca; Mirella Fraquelli; Giovanni Casazza; Cristina Manzotti; Davor Štimac; Damir Miletic
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

Review 5.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

Review 6.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

7.  Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Bang-Bin Chen; Takamichi Murakami; Tiffany Ting-Fang Shih; Michiie Sakamoto; Osamu Matsui; Byung-Ihn Choi; Myeong-Jin Kim; Jeong Min Lee; Ren-Jie Yang; Meng-Su Zeng; Ran-Chou Chen; Ja-Der Liang
Journal:  Liver Cancer       Date:  2015-10-15       Impact factor: 11.740

8.  Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.

Authors:  Sahar Semaan; Naik Vietti Violi; Sara Lewis; Manjil Chatterji; Christopher Song; Cecilia Besa; James S Babb; M Isabel Fiel; Myron Schwartz; Swan Thung; Claude B Sirlin; Bachir Taouli
Journal:  Eur Radiol       Date:  2019-10-31       Impact factor: 5.315

9.  How to Best Detect Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: Gadoxetic Acid-Enhanced MRI versus Contrast-Enhanced CT.

Authors:  Jae Seok Bae; Jeong Min Lee; Jeong Hee Yoon; Siwon Jang; Jin Wook Chung; Kyung Bun Lee; Nam-Joon Yi; Jeong-Hoon Lee
Journal:  Liver Cancer       Date:  2020-01-28       Impact factor: 11.740

10.  Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China.

Authors:  Xiaoning He; Jing Wu; Anke-Peggy Holtorf; Harald Rinde; Shuangshuang Xie; Wen Shen; Jiancun Hou; Xuehua Li; Ziping Li; Jiaming Lai; Yuting Wang; Lin Zhang; Jian Wang; Xuesong Li; Kuansheng Ma; Feng Ye; Han Ouyang; Hong Zhao
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.